论文部分内容阅读
目的:分析二肽基肽酶-4抑制剂致大疱性类天疱疮的发生规律及特点,为安全用药提供参考。方法:检索中国学术期刊全文数据库、维普中文科技期刊数据库、万方数据库和Pubmed数据库收载的二肽基肽酶-4抑制剂致大疱性类天疱疮文献并进行分析。结果:21例不良反应中,男性11例,女性10例,年龄60岁及以上患者20例(95.2%)。21例患者中,服用维格列汀者15例,服用西格列汀者3例,服用利拉列汀者3例。用药至发生大疱性类天疱疮的时间为1~37个月,平均时间8个月。结论:临床医师应了解二肽基肽酶-4抑制剂致大疱性类天疱疮的规律和特点,加强用药监测,以便及时发现和处理大疱性类天疱疮。
OBJECTIVE: To analyze the occurrence and characteristics of pemphigus induced by dipeptidyl peptidase-4 inhibitor and to provide a reference for safe drug use. Methods: Literature of bullous pemphigoid was searched and analyzed in the full-text database of Chinese academic journals, VIP database of Chinese scientific and technical journals, Wanfang database and Pubmed database. Results: Of 21 adverse reactions, 11 were male, 10 were female, and 20 (95.2%) were patients aged 60 and over. Of the 21 patients, 15 were on vildagliptin, 3 were on sitagliptin, and 3 were on lenaligliptin. The medication to bullous pemphigoid occurs for 1 to 37 months, with an average time of 8 months. Conclusion: Clinicians should understand the rules and characteristics of dipeptidyl peptidase-4 inhibitor in bullous pemphigoid, and strengthen the monitoring of medication in order to detect and treat bullous pemphigoid in time.